MR of carcinoma-specific monoclonal antibody conjugated to monocrystalline iron oxide nanoparticles: The potential for noninvasive diagnosis

American Journal of Neuroradiology

Volumn 17, Issue 3, 1996, Pages 411-418

  Remsen, Laura G ^a   McCormick, Christopher I ^c   Roman Goldstein, Simon ^b   Nilaver, Gajanan ^a,b   Weissleder, Ralph ^d   Bogdanov, Alexei ^d   Hellström, Karl E ^e   Hellström, Ingegerd ^e   Kroll, Robert A ^a   Neuwelt, Edward A ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

Author keywords

Animal studies; Antigens and antibodies; Brain neoplasms, magnetic resonance; Carcinoma

Indexed keywords

IRON OXIDE; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TUMOR; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; IMAGE ENHANCEMENT; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CARCINOMA, SMALL CELL; CONTRAST MEDIA; EPITOPES; FEMALE; FERROSOFERRIC OXIDE; HUMANS; INJECTIONS, INTRA-ARTERIAL; INJECTIONS, INTRAVENOUS; IRON; MAGNETIC RESONANCE IMAGING; MICE; NEOPLASM TRANSPLANTATION; OXIDES; RATS; RATS, NUDE; TRANSPLANTATION, HETEROLOGOUS;

EID: 9244257373     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Davis PC, Hudgins PA, Peterman SB, Hoffman JC. Diagnosis of cerebral metastases: double-dose delayed CT vs. contrast-enhanced MR imaging. AJNR Am J Neuroradiol 1991;12:293-300
2. Unger EC, Totty WG, Neufeld DM, et al. Magnetic resonance imaging using gadolinium labeled monoclonal antibody. Invest Radiol 1985;20:693-699
3. 2a antibody that reacts with most human carcinomas. Proc Natl Acad Sci (USA) 1986;83:7059-7063
4. Hellström I, Horn D, Linsley P, Brown JP, Brankovan V, Hellström KE. Monoclonal mouse antibodies raised against human lung carcinoma. Cancer Res 1986;46:3917-3923
5. Goodman GE, Hellström I, Brodzinsky L, et al. Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer. J Clin Oncol 1990;8:1083-1092
6. Nilaver G, Rosenbaum LC, Hellström KE, Hellström I, Neuwelt EA. Identification of neurophysin immunoreactivity in hypothalamus by a monoclonal antibody to a carcinoma cell surface antigen. Neuroendocrinol 1990;51:565-571
7. Barnett PA, Roman-Goldstein S, Ramsey F, et al. Differential permeability and quantitative MR imaging of a human lung carcinoma brain xenograft in the nude rat. Am J Pathol 1992;146:436-449
8. Neuwelt, EA, Weissleder R, Nilaver G, et al. Delivery of virus-sized iron oxide particles to rodent CNS neurons. Neurosurgery 1994;34:777-784
9. Neuwelt EA, Barnett PA, Ramsey FL, Hellström KE, McCormick CI. Dexamethasone decreases the delivery of tumor-specific monoclonal antibody to both intracerebral and subcutaneous tumor xenographs. Neurosurgery 1993;33:478-484
10. Roman-Goldstein SM, Barnett PA, McCormick CI, et al. Effects of Gd-DTPA after osmotic BBB disruption in a rodent model: toxicity and MR findings. J Comput Assist Tomogr 1994;18:731-736
11. Neuwelt EA, Barnett PA, Hellström KE, et al. Delivery of melanoma-specific immunoglobulin monoclonal antibody and Fab fragments to normal brain utilizing osmotic blood-brain barrier disruption. Cancer Res 1988;48:4725-4729
12. Neuwelt EA. Blood-brain barrier disruption in the treatment of brain tumors: animal studies. In: implications of the Blood-Brain Barrier and Its Manipulation, vol 2. Clinical Implications. New York: Plenum Press, 1989:107-194
13. Neuwelt EA, Goldman D, Dahlborg SA, et al. Primary CMS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 1991;9:1580-1590
14. Neuwelt EA, Barnett PA, Hellström KE, Hellström I, McCormick CI, Ramsey FL. The effect of blood-brain barrier on intact and fragmented monoclonal antibody localization in intracerebral human carcinoma xenografts. J Nucl Med 1994;35:1831-1841
15. Kelly PJ, Dumas-Duport C, Kispert DB. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg 1987;66:865-874
16. Patchell RA, Tibbs PAS, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322:494-500
17. Patchell RA, Cirrincione C, Thaler HT, Galicich JH, Kim JH, Posner JB. Single brain metastases: surgery plus radiation or radiation alone. Neurology 1986;36:447-453
18. Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, Josephson L. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 1990;175:489-493
19. Weissleder R, Lee AS, Khaw BA, Shen T, Brady TJ. Antimyosin-labeled monocrystalline iron oxide allows detection of myocardial infarct: MR antibody imaging. Radiology 1992;182:381-385
20. Shen T, Weissleder R, Papisov M, Bogdanov A, Brady TJ. Monocrystalline iron oxide nanocompounds (MION): physicochemical properties. Magn Reson Med 1993;29:599-604
21. Bulte JWM, deJonge MWA, Kamman RL, Zuiderveen F, The TH, deLeij L. Magnetite as a potent contrast-enhancing agent in magnetic resonance imaging to visualize blood-brain barrier disruption. Acta Neurochir 1993;57:30-34
22. Haacke EM. Image behavior: resolution, signal-to-noise, contrast and artifacts. In: Modic MT, ed. Magnetic Resonance Imaging of the Spine. St Louis: Mosby Year Book, 1989:1-34
23. Weissleder R, Bogdanov A, Papisov M. Drug targeting in magnetic resonance imaging. Magn Reson Imaging 1992;8:55-63
24. Weissleder R, Elizondo G, Wittenberg J, Lee AS, Josephson L, Brady TJ. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology 1990;175:494-498